First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC

(MedPage Today) -- SINGAPORE -- Adding the investigational combination of PD-L1 inhibitor benmelstobart and antiangiogenic tyrosine kinase inhibitor anlotinib to first-line chemotherapy significantly improved survival in extensive-stage small...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news